• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "呼吸衰竭" 89 results
        • Nursing Effect Observation of 60 Cases of COPD Combined with Respiratory Failure

          目的:探討慢性阻塞性肺病(慢阻肺)合并呼吸衰竭的臨床護理及其預后之間的關系,為臨床提供慢阻肺合并呼吸衰竭患者的護理經驗及病例資料。方法:對2008年3月至2009年5月間在我院住院治療的60例確診為慢阻肺合并呼吸衰竭的患者,均采用貫序通氣治療,營養支持治療,以及常規氧療,根據護理期間營養支持治療中是否接受靜脈點滴脂肪乳而劃分為兩組,各30例。結果:接受完全腸道外營養患者的治療時間較未接受者短,治愈率優于未接受者(927%比50%),沒有死亡者(0比10%)。結論:有效的護理方法,尤其是恰當的營養支持治療,對慢肺阻合并呼吸衰竭患者具有極其重要的意義。

          Release date:2016-08-26 02:21 Export PDF Favorites Scan
        • Efficacy of noninvasive positive pressure ventilation by helmet in adults with acute respiratory failure: a meta-analysis

          Objective To systematically review the efficacy of noninvasive positive pressure ventilation (NPPV) by helmet in adults with acute respiratory failure. Methods Randomized controlled trials (RCTs) or cohort studies about noninvasive positive pressure ventilation (NPPV) by helmet in adults with acute respiratory failure were retrieved in PubMed, The Cochrane Library (Issue 11, 2016), Web of Science, EMbase, CBM, CNKI and WanFang Data databases from inception to November 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Stata 12.0 software was then used to perform meta-analysis. Results A total of eight studies were included. The results of meta-analysis showed that, NPPV by helmet could significantly reduce the carbon dioxide partial pressure (cohort study: SMD=–0.46, 95%CI –0.75 to –0.18, P=0.001), tracheal intubation rate (RCT: OR=0.36, 95%CI 0.17 to 0.77, P=0.008) and hospital mortality (RCT: OR=0.48, 95%CI 0.24 to 0.98, P=0.044), improve the positive end expiratory pressure (RCT: SMD=1.27, 95%CI 0.87 to 1.67, P<0.05) and respiratory status (RCT: SMD=–0.45, 95%CI –0.81 to –0.08,P=0.017). There was no significant difference in the duration of NPPV(cohort study: OR=–0.20, 95%CI –0.50 to 0.09, P=0.177; RCT: OR=–0.24, 95%CI –0.86 to 0.38, P=0.445). Conclusion NPPV by helmet can reduce the carbon dioxide partial pressure, tracheal intubation rate, hospital mortality and improve the positive end expiratory pressure, respiratory status. But the effects in the duration of NPPV and oxygenation index are uncertain. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.

          Release date:2017-11-21 03:49 Export PDF Favorites Scan
        • Analyze the Reason for the Success of Weaning of Patients with Longterm Mechanical Ventilation

          目的:分析長期機械通氣患者脫機成敗原因,提高脫機成功率。方法:針對本院2003年5月至2008年10月近6年ICU172例長期機械通氣患者成敗原因進行分析。結果:總脫機成功率90.69%。脫機失敗率 9.31%。結論:長期機械通氣患者多存在多種因素的共同參與,如營養不良、全身衰弱、呼吸功能不全、通氣泵衰竭和心理因素等,增加了脫機的難度,進而出現撤機困難。

          Release date:2016-09-08 10:02 Export PDF Favorites Scan
        • 無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭的護理

          【摘要】 目的 探討無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭的護理措施。 方法 回顧性分析2006年1月-2008年12月使用無創正壓通氣治療合并呼吸衰竭的慢性阻塞性肺疾病患者的臨床資料,比較其使用呼吸機前后的癥狀、舒適性、體溫、心率及血氣分析的變化。 結果 使用無創正壓通氣治療后患者癥狀改善,無明顯不適感,體溫、心率趨于平穩,缺氧、高碳酸血癥得到明顯改善。 結論 無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭易于護理,效果顯著。

          Release date:2016-09-08 09:50 Export PDF Favorites Scan
        • 慢性阻塞性肺病并發急性腎損傷的臨床分析

          【摘要】 目的 總結慢性阻塞性肺疾病(COPD)并發急性腎損傷(AKI)的發病機制、臨床特點及救治經驗。 方法 回顧性分析2008年收治的COPD并發AKI的80例患者的臨床資料,初步分析其臨床表現、并發癥、呼衰程度與AKI的關系,治療措施與預后的關系。 結果 80例COPD并發的AKI治愈46例(57.5%),好轉16例(20%),轉為CKD3例(3.75%),死亡15例(18.75%)。 結論 COPD患者是AKI的高危人群,發病率高,并發AKI后易發生多器官功能衰竭(MOF),死亡率增加。早期積極治療可使多數患者發生的AKI逆轉。對于COPD患者避免誘發加重因素,早期識別和早期干預AKI十分重要。

          Release date:2016-09-08 09:50 Export PDF Favorites Scan
        • 局部肺葉灌洗治療合并呼吸衰竭的重癥肺泡蛋白沉積癥三例并文獻復習

          目的探討局部肺葉灌洗治療合并呼吸衰竭的重癥肺泡蛋白沉積癥(pulmonary alveolar proteinosis,PAP)的可行性及安全性。方法回顧3例合并呼吸衰竭的PAP患者通過局部肺葉灌洗后逐漸自愈的診治經過,并復習相關中外文獻進行總結分析。結果3例患者均為男性,年齡50~55歲,有長期的粉塵、生物燃料或者消毒物質的密切接觸史,以“咳嗽、呼吸困難”入院。入院時呼吸空氣動脈血氣分析均提示I型呼吸衰竭,胸部高分辨率CT(high-resolution computed tomography,HRCT)呈“鋪路石征”;1例患者取支氣管肺泡灌洗液、2例患者取支氣管鏡肺活檢行過碘酸–雪夫染色結果均為陽性而確診PAP。2例患者接受了1次局部肺葉灌洗,1例患者接受了2次局部肺葉灌洗,灌洗后1~5 d復查胸部HRCT與灌洗前相仿,但呼吸困難癥狀均較前明顯改善,動脈血氣分析提示呼吸衰竭糾正。出院后密切隨診1~6個月,患者均無呼吸困難復發,胸部HRCT提示雙肺彌漫性斑片影幾乎全部吸收。截止到2021年1月,在中國知網、維普、萬方等數據庫以“肺泡蛋白沉積癥”和“支氣管肺泡灌洗”為檢索詞,在PubMed數據庫以“pulmonary alveolar proteinosis”和“lobar lavage”為關鍵詞,共檢索到相關中英文文獻64篇,其中合并呼吸衰竭的重癥PAP患者43例。大部分報道是利用反復、多次的局部肺葉灌洗,將雙肺的所有肺葉逐一進行灌洗,最多者局部肺葉灌洗次數多達20次,時間跨度達4個月;一些研究是將局部肺葉、肺段灌洗作為“預洗”或者“橋梁”,改善臨床癥狀后再進行全肺灌洗;一些研究對比了接受全肺灌洗或肺葉灌洗患者的治療效果,認為兩者療效相仿,大部分患者僅需要1次灌洗,臨床癥狀即有明顯改善。結論肺葉局部灌洗治療合并呼吸衰竭的重癥PAP是安全有效的,同時在1~2次局部肺葉灌洗后,1~6個月隨訪PAP患者病情呈自愈傾向,短時間內反復、多次灌洗可能是不必要的。

          Release date:2023-03-02 05:23 Export PDF Favorites Scan
        • Clinical Analysis on Invasive-noninvasive Sequential Mechanical Ventilation in the Treatment of Chronic Obstructive Pulmonary Disease Complicated by Type Ⅱ Respiratory Failure

          ObjectiveTo observe the clinical efficacy of invasive-noninvasive sequential mechanical ventilation in the treatment of chronic obstructive pulmonary disease (COPD) complicated by type Ⅱ respiratory failure. MethodsA total of 100 patients with COPD complicated with type Ⅱ respiratory failure from March 2013 to April 2014 were randomly divided into control group and study group (with 50 patients in each). While the control group was given continuous invasive ventilation treatment, the study group was treated with invasive-noninvasive sequential ventilation. The ventilation time, Intensive Care Unit (ICU) monitoring and hospitalization time, the serum concentrations of C-reactioin protein (CRP) before and after treatment and the ventilator associated pneumonia (VAP) and hospital mortality rate were observed and compared between the two groups. ResultsFor patients in the study group, ICU monitoring time, ventilation time and hospitalization time were (9.4±8.1), (10.3±5.8), and (14.7±8.2) days, respectively, significantly shorter than those in the control group[(17.5±10.8), (15.2±7.7), and (22.8±7.4) days] (P<0.05). The incidence of VAP and nosocomial VAP mortality in the study group were 4.0% and 2.0% respectively, which were significantly lower than those in the control group (22.0% and 20.0%), and the differences were statistically significant (P<0.05). ConclusionIn the clinical treatment of COPD patients with type Ⅱ respiratory failure, invasive-noninvasive sequential ventilation treatment is effective in shortening the duration of ventilation and hospitalization time, controlling the incidence of VAP, and reducing the mortality rate, which is worthy of clinical popularization.

          Release date: Export PDF Favorites Scan
        • Analysis of 1,531 Hospitalized Patients of Respiratory Disease with Mechanical Ventilation

          ObjectiveTo analyze hospitalized patients of respiratory diseases with mechanical ventilation (MV). MethodsHospitalized patients with or without MV were enrolled into the current study from January 2010 to December 2014. Patients' characteristics including age and sex, type of illness and costs of hospital treatment were retrospectively analyzed. ResultsA total of 9,539 patients were hospitalized into Department of Respiratory Medicine, The General Hospital of Shenyang Military Area Command in the past 5 years. Of them, 1,531 (16.0%) patients were treated with MV, 764 of the 1,531 (49.9%) patients received non-invasive mechanical ventilation (NIMV), 135 of the 1,531 (8.8%) received invasive mechanical ventilation (IMV), and 632 of the 1,531 (41.3%) received NIMV plus IMV. The percentage of patients older than 65 years in the three groups as above were 71.3%, 63.0% and 72.2%, significantly higher than the Non-MV group's 47.7% (P<0.05); the percentage of males were 52.7%, 82.2% and 63.3% respectively, the later two groups was significantly higher than the Non-MV group's 59.2% (P<0.05); the percentage of ICU admission were 67.0%, 70.4% and 82.8%, significantly higher than the Non-MV group's 24.0% (P<0.05); the percentage of type Ⅰ respiratory failure were 12.4%, 29.6% and 12.4%, the later two groups was significantly higher than the Non-MV group's 13.2% (P<0.05); the percentage of type Ⅱ respiratory failure were 76.6%, 17.8% and 47.0%, all were significantly higher than the Non-MV group's 7.6% (P<0.05). Twenty-one kinds of common co-morbidities for respiratory hospitalized patients were analyzed and it was found that MV patients were likely to have more co-morbidities. Compared to Non-MV group, IMV group had more co-morbidities of type Ⅰ or type Ⅱ respiratory failure caused by pneumonia, bronchiectasis and other infectious diseases and concomitant with hypoalbuminemia, gastrointestinal bleeding and liver and kidney dysfunction and cerebrovascular disease, with statistically significant differences (P<0.05); NIMV group had more co-morbidities of type Ⅱ respiratory failure caused by chronic bronchitis, emphysema, pulmonary heart disease and other chronic airway diseases, and concomitant with coronary heart disease, heart failure, cerebrovascular disease and renal dysfunction, with statistically significant differences (P<0.05); the co-morbidity spectrum of NIMV plus IMV group was between those of IMV and NIMV groups, but more similar to that of IMV group. The high risk factors for IMV were pneumonia, hypoalbuminemia, gastrointestinal bleeding, and cerebrovascular disease; for NIMV were chronic bronchitis, emphysema, pulmonary heart disease, type Ⅱ respiratory failure and cardiac dysfunction. Cost analysis showed that average cost of Non-MV, NIMV, IMV, and NIMV plus IMV patients were 16 359 yuan, 31 872 yuan, 66 924 yuan, and 98 648 yuan respectively, in which the expense of NIMV plus IMV patients was vastest. ConclusionsHospitalized patients receiving MV therapy tend to be older, stay in ICU, complicated with respiratory failure and multiple co-morbidities. Respiratory failure by chronic obstructive airways disease is more often treated with NIMV, but respiratory failure by lung infection often need IMV.

          Release date: Export PDF Favorites Scan
        • Predictive Value of Simplified Version of Clinical Pulmonary Infection Score for Efficacy of Noninvasive Ventilation Therapy in Patients with Acute Exacerbation of COPD

          Objective To investigate the influence of pulmonary infection on noninvasive ventilation ( NIV) therapy in hypercapnic acute respiratory failure ( ARF) due to acute exacerbation of chronic obstructive pulmonary disease ( AECOPD) , and evaluate the predictive value of simplified version of clinical pulmonary infection score ( CPIS) for the efficacy of NIV therapy in ARF patients with AECOPD. Methods Eighty-four patients with ARF due to AECOPD were treated by NIV, and were divided into a successful group and an unsuccessful group by the therapeutic effect of NIV. The CPIS and simplified version of CPIS between two groups was compared. The predictive value of simplified version of CPIS for the efficacy of NIV wasevaluated using ROC curve analysis. Results The CPIS and the simplified version of CPIS of the successful treatment group ( 4. 0 ±2. 8, 3. 2 ±2. 4) were lower than those of the unsuccessful group ( 8. 0 ±2. 1, 7. 2 ±1. 8) significantly ( P =0. 006, 0. 007) . The area under ROC curve ( AUC) of CPIS and simplified version of CPIS were 0. 884 and 0. 914 respectively, the cut oint of CPIS and simplified version of CPIS were 6 ( sensitivity of 78. 0% , specificity of 91. 2% ) and 5 ( sensitivity of 80. 0% , specificity of 91. 2% ) respectively. Conclusions The level of pulmonary infection is an important influencing factor on the therapeutic effect of NIV in patients with ARF due to AECOPD. Simplified version of CPIS is a helpful predictor for the effect of NIV on ARF of AECOPD.

          Release date: Export PDF Favorites Scan
        • Clinical Analysis of Acute Myocardial Infarction in Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

          Objective To investigate the clinical characteristics of acute myocardial infarction ( AMI) in elderly patients with acute exacerbation of chronic obstructive pulmonary disease ( AECOPD) .Methods Clinical data of 16 elderly patients with AECOPD and AMI from may 2007 to December 2009 were reviewed. Meanwhile, 128 elderly AECOPD patients without AMI were analyzed as control. Results Neither the AMI group nor the control group had typical precordial pain, conscious disturbance, andhypotension. Compared with the control group, the main symptoms of the AMI group were worsening of chest tightness and dyspnea( 16 /16 vs. 4/128, P lt;0. 01) ,most of which accompanying fever( 11/16 vs. 6/128, P lt;0. 05) and anorexia ( 10/16 vs. 23 /128, P lt; 0. 05) . The incidence of patches-like shadow on chest X-rayincreased ( 16 /16 vs. 62/128, P lt;0. 05) , PaO2 ( mm Hg) decreased ( 43. 72 ±3. 64 vs. 82. 26 ±11. 41, P lt;0. 001) , the red blood cell count ( ×1012 /L) increased ( 6. 43 ±0. 42 vs. 4. 11 ±1. 24, P lt; 0. 05) , the concentration of total cholesterol ( mmol /L) increased ( 6. 51 ±0. 84 vs. 3. 93 ±1. 14, P lt; 0. 05) , the needfor invasive mechanical ventilation increased ( 13/16 vs. 11 /128, P lt; 0. 05) , the days in hospital were prolonged ( 35 ±13 vs. 11 ±3, P lt; 0. 01) , the cost ( 1000 RMB) increased( 32 ±11 vs. 7. 6 ±2. 8, P lt;0. 01) , and the mortality also increased ( 2/16 vs. 3 /128, P lt;0. 01) . Conclusion AMI should be alerted in the case of sudden exacerbation of chest tightness and dyspnea in elderly patients with AECOPD.

          Release date:2016-08-30 11:54 Export PDF Favorites Scan
        9 pages Previous 1 2 3 ... 9 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜